Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 606 clinical trials
Featured trial
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy.  

refractory multiple myeloma
daratumumab
  • 186 views
  • 10 May, 2022
  • 28 locations
Featured trial
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

bortezomib
multiple myeloma
lenalidomide
chronic myelomonocytic leukaemia
myelodysplastic syndromes
  • 1 views
  • 15 Sep, 2022
  • 12 locations
A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.

  • 0 views
  • 18 Sep, 2022
  • 12 locations
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will …

  • 0 views
  • 23 Sep, 2022
  • 5 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Primary Objectives: Part 1 (dose finding, experimental substudies): -To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …

  • 1 views
  • 27 Jul, 2022
  • 17 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Primary Objectives: Part 1 (dose finding, experimental substudies): -To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …

  • 23 views
  • 30 Sep, 2022
  • 19 locations
Familial Dysglobulinemia (PreFamDys)

Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. Myeloma commonly evolves

Accepts healthy volunteers
  • 26 views
  • 10 Apr, 2022
  • 31 locations
HB10101 Multiple Myeloma

It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma Patients

  • 1 views
  • 03 Feb, 2021
  • 1 location
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2, single-arm, open, non-randomized, multicenter study of the SINE compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. 100 mg selinexor (on days 1, 8, 15 and 22), plus 40 mg dexamethasone (20 mg IV the day of daratumumab and selinexor and 20 mg oral administration the …

monoclonal protein
bortezomib
lenalidomide
proteasome inhibitor
colony stimulating factor
  • 22 views
  • 05 Mar, 2022
  • 15 locations
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.

  • 1 views
  • 10 Aug, 2022
  • 2 locations